EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation

Tongguan Tian, Xiao Xie, Wanwan Yi, Yuefan Zhou, Yixin Xu, Zhenxiang Wang, Junjing Zhang, Mingen Lin, Ruonan Zhang, Zhongwei Lv, Xinxing Li, Lei Lv und 1 weitere

Cell Reports · 2023

DOI: 10.1016/j.celrep.2023.113362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Tongguan Tian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences a…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upregulation of FGL1 helps tumors escape from immune surveillance, and therapeutic antibodies targeting FGL1 have potential as another immune checkpoint inhibitor. However, the underlying mechanism of high FGL1 protein level in cancers is not well defined. Here, we report that FBXO38 interacts with and ubiquitylates FGL1 to negatively regulate its stability and to mediate cancer immune response. Depletion of FBXO38 markedly augments FGL1 abundance, not only suppressing CD8+ T cell infiltration and enhancing immune evasion of tumor but also increasing inflammation in mice. Importantly, we observe a negative correlation of FBXO38 with FGL1 and IL-6 in non-small cell lung cancer specimens. FGL1 and IL-6 levels positively correlate with TNM (tumor, lymph node, metastasis) stages, while FBXO38 and the infiltrating CD8+ T cells negatively correlate with TNM stages. Our study identifies a mechanism regulating FGL1 stability and a target to enhance the immunotherapy and suggests that the combination of anti-FGL1 and anti-IL-6 is a potential therapeutic strategy for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsMiceCD8-Positive T-LymphocytesInflammationInterleukin-6UbiquitinationFibrinogenF-Box Proteins

Stichwörter der Autor:innen

CP: CancerCP: ImmunologyFBXO38FGL1immunotherapynon-small cell lung cancerubiquitination

Substanzen

Interleukin-6Fgl1 protein, mouseFibrinogenFbxo38 protein, mouseF-Box Proteins

Autor:innen und Institutionen

  • Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200065, China.
  • Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
  • Department of Nuclear Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
  • MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
  • MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China. Electronic address: lvlei@fudan.edu.…
  • Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200065, China. Electronic a…

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Tian, T., Xie, X., Yi, W., Zhou, Y., Xu, Y., Wang, Z., Zhang, J., Lin, M., Zhang, R., Lv, Z., Li, X., Lv, L., & Xu, Y. (2023). FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113362

Vancouver

Tian T, Xie X, Yi W, Zhou Y, Xu Y, Wang Z, et al. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Reports. 2023. doi:10.1016/j.celrep.2023.113362

BibTeX
@article{Tian2023,
  author = {Tian, Tongguan and Xie, Xiao and Yi, Wanwan and Zhou, Yuefan and Xu, Yixin and Wang, Zhenxiang and Zhang, Junjing and Lin, Mingen and Zhang, Ruonan and Lv, Zhongwei and Li, Xinxing and Lv, Lei and Xu, Yanping},
  title = {FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation},
  journal = {Cell Reports},
  year = {2023},
  doi = {10.1016/j.celrep.2023.113362}
}
Kostenlos starten →